In addition to block CD47/SIRPα checkpoint alone, combined SIRPα/CD47 with PD-1/PD-L1 blockade enhances the efficiency of antitumor immunotherapy 41, 47, 48, suggesting that SIRPα-CD47 axis blockade could enhance PD-1/PD-L1 blockade therapy for cancer. Here, SIRPA is linked to cancer.